# Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

> **NCT06933056** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Michigan** · enrollment: 20 (estimated)

## Conditions studied

- Platelet Function and Reactivity Tests

## Interventions

- **DRUG:** Sotagliflozin (SOTA) followed by 3 drugs in a random order
- **DRUG:** Aspirin followed by 3 drugs in a random order
- **DRUG:** Clopidogrel followed by 3 drugs in a random order
- **DRUG:** Eliquis followed by 3 drugs in a random order

## Key facts

- **NCT ID:** NCT06933056
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933056, "Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06933056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*